Introduction {#s1}
============

Respiratory infections, including tuberculosis, represent one of the leading causes of morbidity and mortality across the world. They represent the deadliest communicable diseases causing 3.0 million deaths worldwide in 2016 \[[@C1]\]. The burden of respiratory infections can be unbearable for some health systems: they represent one of the most common reasons for doctor visits, regardless of age and sex \[[@C2]\].

Although respiratory infections have been identified as a mandatory topic in the education and training of respiratory physicians, the specialty has been faced with several challenges to implement training. There are ongoing discussions surrounding what is included and excluded epidemiologically within the parameters of respiratory infections. Thus it is no surprise that, at present, the vast majority of European countries do not yet have a formal system for educating respiratory physicians, at a specialty level, on the knowledge and skills considered essential in the diagnosis, treatment and prevention of respiratory infections. Furthermore, European countries have very different resources dedicated to the continuing development of respiratory professionals.

Keeping these educational and training challenges in mind, the European Respiratory Society (ERS) decided to support a group of experts in respiratory infections to define the core knowledge and skills considered essential to manage respiratory infections. The ERS respiratory infections educational task force was founded in 2014 and included 13 experts from six European countries (Italy, Germany, UK, the Netherlands, Spain and Greece). The task force had two main aims: 1) to develop a syllabus to guide the national training and education of respiratory physicians in the field of respiratory infections, and 2) to help structure ERS educational activities on respiratory infections.

Target audience {#s2}
===============

As previously outlined \[[@C3]\], the target audience for the syllabus are qualified respiratory physicians with a special interest in respiratory infections. Based on the situational analysis and the Delphi surveys, the target audience also includes infectious diseases specialists, intensive care unit specialists, internists, trainees, researchers and microbiologists, working in public hospitals or holding an academic position.

Methods {#s3}
=======

The approach, methods, and processes used in this project have been adapted from the ERS developed educational harmonisation framework, which, to date, has been used in the development of seven postgraduate curricula ([www.ersnet.org/professional-development/ers-curriculum-design-a-summary-of-projects](www.ersnet.org/professional-development/ers-curriculum-design-a-summary-of-projects)) and four specialised skills-based training programmes \[[@C4]\].

To develop the syllabus, a list of key topics was identified by the expert task force. A modified Delphi technique was applied to these topics to reach consensus. The Delphi technique is a group facilitation method that seeks to obtain consensus on the opinions of experts through a series of structured questionnaires \[[@C5]\]. Research and methods outlined by H[eiko]{.smallcaps} \[[@C6]\] were used to guide the decisions taken at various stages of this study, for example survey design, undertaking data collection and analysis.

The Delphi process was phased in three rounds ([figure 1](#F1){ref-type="fig"}). Members of ERS Assembly 10 (respiratory infections) and national experts were asked to complete an online questionnaire, which was then processed by the ERS office. The results were presented to the task force for more detailed discussion. The decisions derived from these consultations were integrated into the next Delphi round (Delphi 1). It is to be noted that although the same respondents were contacted in each round, there was a drop off in the number of responses between rounds. Respondents were asked to rate in terms of agreement whether sections should be included (mandatory or optional) or excluded. A Likert scale from 1 (strongly disagree) to 5 (strongly agree) was chosen to ensure measurement reliability over the three different Delphi rounds. Agreement was operationalised through a majority of responses in the top two points of the scale (measured as the sum of frequencies of agree and strongly agree responses). In Delphi studies consensus is considered a necessary, but not sufficient, condition for agreement concerning the inclusion of items \[[@C6]\]. The iteration of rounds was also required to establish the stability dimension for agreement. Stability was defined as "the consistency of responses between successive rounds of a study" \[[@C7]\]. Both consensus and stability dimensions were investigated in the study.

![Overview of the Delphi process.](EDU-0262-2018.01){#F1}

Final syllabus {#s4}
==============

The content of the syllabus was organised in 14 modules, which were considered important and necessary topics or aspects forming the basis of the respiratory infections domain ([table 1](#TB1){ref-type="table"}). Table 1ERS syllabus for postgraduate training in respiratory infections**Module 1. Pathogens (respiratory microbiology)**  1 Respiratory microbiologyMandatory  1.1 Normal bacterial flora   1.2 Classification of respiratory microorganisms  2 Respiratory bacteriaMandatory  2.1 Gram positive   2.2 Gram negative   2.3 Atypicals  3 Respiratory virusesMandatory  3.1 RNA viruses (seasonal and/or pandemic, emerging)   3.2 DNA viruses (seasonal and/or pandemic, emerging)  4 Respiratory fungiMandatory  4.1 *Candida* spp.   4.2 *Aspergillus* spp.   4.3 Pneumocystis   4.4 Other fungi (including *Mucor* spp., *Cryptococcus neoformans*, *Histoplasma capsulatum*, *Coccidioides immitis*, *Blastomyces dermatitidis*, *Paracoccidioides brasiliensis*, Exophiala and Scedosporium)Optional 5 MycobacteriaMandatory  5.1 *Mycobacterium tuberculosis*   5.2 Non-tuberculous mycobacteria (NTM)  6 Antimicrobial resistanceMandatory  6.1 Mechanisms of antibiotic resistance   6.2 Multidrug-resistant (MDR) bacteria   6.3 Risk factors for MDR bacteria   6.4 MDR/extensively drug-resistant (XDR) tuberculosis   6.5 Risk factors for MDR/XDR tuberculosis   6.6 NTM resistance   6.7 Resistance in other microorganisms (anti-fungal and anti-viral resistance)Optional  6.8 Influenza resistanceOptional 7 MicrobiomeOptional**Module 2. Host respiratory defence mechanisms against infection**  1 Natural barriersMandatory  1.1 Cilia/primary ciliary dyskinesia  2 Innate immune systemsMandatory  2.1 Complement   2.2 Cells   2.3 Defensins   2.4 Cytokines   2.5 Inflammation process  3 Adaptive immune systemsMandatory  3.1 Humoral immunity   3.2 Cellular immunity  4 Immune reconstitution inflammatory syndrome (IRIS)Optional 5 Pathophysiology of respiratory infectionsMandatory  5.1 Transmission   5.2 Infection   5.3 Inflammation   5.4 Resolution **Module 3. Epidemiology, burden of disease and risk factors**  1 Epidemiological burden of respiratory infectionsMandatory  1.2 Bacterial infections   1.3 Viral infections   1.4 Fungal infections   1.5 Mycobacterial infections (tuberculosis and NTM)  2 Risk factors for respiratory infections and transmissionMandatory  2.1 Environmental risk factors   2.2 Host risk factors (including other conditions leading to mild immunosuppression, *e.g.* diabetes mellitus)   2.3 Microbial risk factors **Module 4. Diagnostic techniques for respiratory infections**  1 Indication and collection of biological specimensMandatory  1.1 Noninvasive (blood, urine, bronchoalveolar lavage, throat swabs)   1.2 Invasive (sputum, tracheal aspirate, thoracentesis, imaging-guided biopsy, transthoracic fine-needle biopsy)  2 MicroscopyOptional 3 CultureOptional 4 Susceptibility testingOptional 5 Immunological testsOptional  5.1 Interferon-γ release assay (IGRA)   5.2 Tuberculin skin test   5.3 Serology  6 Molecular testingOptional 7 Rapid point-of-care diagnostic tests for viral and bacterial respiratory tract infectionsOptional 8 Imaging techniques in relation to infections (including chest radiography, computed tomography, lung ultrasounds and magnetic resonance imaging)Mandatory**Module 5. General principles of antimicrobial therapy**  1 Antibacterial agentsMandatory  1.1 Classification and activity (including pharmacokinetics/pharmacodynamics (PK/PD) principles)  2 Antiviral agentsMandatory  2.1 Classification and activity (including PK/PD principles)  3 Antifungal agentsMandatory  3.1 Classification and activity (including PK/PD principles)  4 Antimycobacterial agentsMandatory  4.1 Classification and activity (including PK/PD principles)  5 Drug delivery or administrationMandatory  5.1 Oral   5.2 Inhaled   5.3 Intravenous   5.4 Intramuscular  6 Drug--drug interactionMandatory 7 Antimicrobial adverse eventsMandatory  7.1 Haematological side-effects   7.2 Nausea and vomiting   7.3 Diarrhoea including *Clostridium difficile* infection   7.4 Ototoxicity   7.5 Hepatic toxicity   7.6 Nephrotoxicity   7.7 Cardiovascular toxicity  8 Principles of antimicrobial stewardship (including prevention of infection, infection control, adequate and appropriate treatment)Mandatory**Module 6. Common respiratory tract syndromes**  1 Common upper respiratory tract syndromes (including acute infective rhinitis, sinusitis, pharyngitis, epiglottitis, laryngotracheitis)Mandatory 2 Acute bronchitisMandatory 3 BronchiolitisMandatory 4 Exacerbation of asthmaMandatory 5 Exacerbation of chronic obstructive pulmonary disease (COPD)Mandatory 6 Exacerbation of bronchiectasisMandatory 7 Community-acquired pneumonia, including nursing-home pneumoniaMandatory 8 Nosocomial pneumonia, including ventilator-associated pneumoniaMandatory 9 Aspiration pneumoniaMandatory 10 Seasonal influenzaMandatory 11 Extrapulmonary complicationsMandatory**Module 7. Other respiratory infections**  1 Fungal pulmonary infectionsMandatory 2 Lung abscessMandatory 3 NocardiosisMandatory 4 ActinomycosisMandatory 5 Parasitic pneumoniaOptional 6 Travel born respiratory infectionsMandatory**Module 8. Severe viral respiratory infections**  1 VirusesMandatory  1.1 Severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), H1N1, H5N1  2 PandemicsMandatory  2.1 Identification   2.2 Management   2.3 Public health policies **Module 9. Mycobacterial disease**  1 Pulmonary tuberculosisMandatory 2 Extrapulmonary tuberculosisMandatory 3 Latent tuberculosis infectionMandatory 4 Nontuberculous mycobacterial infectionsMandatory**Module 10. Chronic respiratory infections in patients with respiratory disease**  1 AsthmaMandatory 2 COPDMandatory 3 BronchiectasisMandatory 4 Adult cystic fibrosis bronchiectasisMandatory**Module 11. Pulmonary infections in the immunocompromised host**  1 Neutropenic patientsMandatory 2 HIV-infected patientsMandatory 3 Haematological disorders and malignancyMandatory 4 Lung and other solid organ transplant recipientsMandatory 5 Haematopoietic cell transplant recipientsMandatory 6 Secondary immunodeficiency induced by drugs and biologicalsMandatory 7 Primary immune deficiency syndromesMandatory**Module 12. Pleural infections**  1 Parapneumonic effusion and empyemaMandatory 2 PleuritisMandatory  2.1 tuberculosis, bacterial, *etc.* **Module 13. Sepsis**  1 Sepsis, severe sepsis and septic shockMandatory  1.1 Virulence factors involved in sepsis   1.2 Early recognition and management   1.3 Additional therapies   1.4 Biomarkers   1.5 Clinical management **Module 14. Prevention of respiratory infections**  1 VaccinationMandatory  1.1 Influenza vaccination   1.2 Pneumococcal vaccination   1.3 Other vaccinations  2 Other prevention measuresOptional  2.1 Smoking cessation   2.2 Specific preventive management   2.3 Prevention of community-acquired pneumonia   2.4 Dental care   2.5 Aspiration management  3 Infection controlMandatory  3.1 Infection surveillance   3.2 Universal precautions   3.3 Isolation and reverse isolation, including specific microbes in cystic fibrosis and bronchiectasis (*e.g. Pseudomonas*)   3.4 Infectious risks to healthcare workers   3.5 Tuberculosis control and elimination, including Bacillus Calmette--Guérin (BCG) vaccine   3.6 Immunomodulants (synthetic and microbial) 

Conclusion and next steps {#s5}
=========================

The syllabus was developed to clearly define the remit for programme designers in the implementation of training and education for respiratory physicians. ERS is committed to the continuing professional development of respiratory professionals and will be using the ERS respiratory infections syllabus as a basis for several activities in the future, including: External courses, such as the respiratory infections course (*e.g.* the course held in Lisbon, Portugal, June 2018), postgraduate courses at the ERS International Congress, e-learning and other educational activities;Respipedia and other online resources;An ERS professional development programme, focusing on the eight main disease areas.
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